PPARγ as a Novel Therapeutic Target in Lung Cancer
Lung cancer is the leading cause of cancer-related death, with more than half the patients having advanced-stage disease at the time of initial diagnosis and thus facing a poor prognosis. This dire situation poses a need for new approaches in prevention and treatment. Peroxisome proliferator-activat...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2016/8972570 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563749305712640 |
|---|---|
| author | Aravind T. Reddy Sowmya P. Lakshmi Raju C. Reddy |
| author_facet | Aravind T. Reddy Sowmya P. Lakshmi Raju C. Reddy |
| author_sort | Aravind T. Reddy |
| collection | DOAJ |
| description | Lung cancer is the leading cause of cancer-related death, with more than half the patients having advanced-stage disease at the time of initial diagnosis and thus facing a poor prognosis. This dire situation poses a need for new approaches in prevention and treatment. Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. Its involvement in adipocyte differentiation and glucose and lipid homeostasis is well-recognized, but accumulating evidence now suggests that PPARγ may also function as a tumor suppressor, inhibiting development of primary tumors and metastases in lung cancer and other malignancies. Besides having prodifferentiation, antiproliferative, and proapoptotic effects, PPARγ agonists have been shown to prevent cancer cells from acquiring the migratory and invasive capabilities essential for successful metastasis. Angiogenesis and secretion of certain matrix metalloproteinases and extracellular matrix proteins within the tumor microenvironment are also regulated by PPARγ. This review of the current literature highlights the potential of PPARγ agonists as novel therapeutic modalities in lung cancer, either as monotherapy or in combination with standard cytotoxic chemotherapy. |
| format | Article |
| id | doaj-art-067305f800cd400e9ce3b4c40f31cb37 |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-067305f800cd400e9ce3b4c40f31cb372025-02-03T01:12:29ZengWileyPPAR Research1687-47571687-47652016-01-01201610.1155/2016/89725708972570PPARγ as a Novel Therapeutic Target in Lung CancerAravind T. Reddy0Sowmya P. Lakshmi1Raju C. Reddy2Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USALung cancer is the leading cause of cancer-related death, with more than half the patients having advanced-stage disease at the time of initial diagnosis and thus facing a poor prognosis. This dire situation poses a need for new approaches in prevention and treatment. Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. Its involvement in adipocyte differentiation and glucose and lipid homeostasis is well-recognized, but accumulating evidence now suggests that PPARγ may also function as a tumor suppressor, inhibiting development of primary tumors and metastases in lung cancer and other malignancies. Besides having prodifferentiation, antiproliferative, and proapoptotic effects, PPARγ agonists have been shown to prevent cancer cells from acquiring the migratory and invasive capabilities essential for successful metastasis. Angiogenesis and secretion of certain matrix metalloproteinases and extracellular matrix proteins within the tumor microenvironment are also regulated by PPARγ. This review of the current literature highlights the potential of PPARγ agonists as novel therapeutic modalities in lung cancer, either as monotherapy or in combination with standard cytotoxic chemotherapy.http://dx.doi.org/10.1155/2016/8972570 |
| spellingShingle | Aravind T. Reddy Sowmya P. Lakshmi Raju C. Reddy PPARγ as a Novel Therapeutic Target in Lung Cancer PPAR Research |
| title | PPARγ as a Novel Therapeutic Target in Lung Cancer |
| title_full | PPARγ as a Novel Therapeutic Target in Lung Cancer |
| title_fullStr | PPARγ as a Novel Therapeutic Target in Lung Cancer |
| title_full_unstemmed | PPARγ as a Novel Therapeutic Target in Lung Cancer |
| title_short | PPARγ as a Novel Therapeutic Target in Lung Cancer |
| title_sort | pparγ as a novel therapeutic target in lung cancer |
| url | http://dx.doi.org/10.1155/2016/8972570 |
| work_keys_str_mv | AT aravindtreddy ppargasanoveltherapeutictargetinlungcancer AT sowmyaplakshmi ppargasanoveltherapeutictargetinlungcancer AT rajucreddy ppargasanoveltherapeutictargetinlungcancer |